Dar Al Dawa is a MENA-wide leader in Pharmaceutical and consumer health products. With a history of more than 40 years. As a fully integrated Pharmaceutical company, we have a long established customer-centered approach to developing, producing, marketing and commercializing high-quality affordable medicines and wellness consumer products in emerging markets, with more than 900 people serving patients in more than 40 countries throughout Middle East, North Africa and Europe. Dar Al Dawa possesses a high-performance business drive combining unparalleled experience, comprehensive capabilities across all management, development, production, technology, marketing and commercial teams and business functions. According to Jordan’s Drug owners association, Dar Al Dawa is ranked first in 2013 considering the number of new drug registration submissions. The company generated gross revenues of US$60 million for the fiscal year ended Dec 31, 2012, an increase of 5.6% versus 2011 results. We are focused on four core therapy areas – anti-infectives, respiratory, musculoskeletal and increasingly on CNS and CVS– where we can apply our expertise and resources more effectively by taking advantage of the knowledge of our integrated teams. Our goal is to develop and commercialize our compounds and those of our collaboration partners in selected markets where a company of our size can compete successfully for targeted disease states.